Table 2.
Second line chemotherapy received by patients with advanced biliary cancer
| Regimen | N (%) |
|---|---|
| 5-fluorouracil-based | 124 (62.6%) |
| Gemcitabine-based | 36 (18.1%) |
| Intrahepatic FUDR | 11 (5.5%) |
| Other | 27 (13.6%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.